{
    "title": "113_s2862",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Regulatory Transparency, Patient \nAccess, and Effective Drug Enforcement Act of 2014''.\n\nSEC. 2. SCHEDULING OF SUBSTANCES INCLUDED IN NEW FDA-APPROVED DRUGS.\n\n    Section 201 of the Controlled Substances Act (21 U.S.C. 811) is \namended by inserting after subsection (h) the following:\n    ``(i) Within 45 days of receiving a recommendation from the \nSecretary to add a drug or substance that has never been marketed in \nthe United States to a schedule under this title, the Attorney General \nshall, without regard to the findings required by subsection (a) of \nthis section or section 202(b), issue an interim final rule, under the \nexception for good cause described in subparagraph (B) of section \n553(b) of title 5, United States Code, placing the drug or substance \ninto the schedule recommended by the Secretary. The interim final rule \nshall be made immediately effective under section 553(d)(3) of title 5, \nUnited States Code.''.\n\nSEC. 3. ENHANCING NEW DRUG DEVELOPMENT.\n\n    Section 302 of the Controlled Substances Act (21 U.S.C. 822) is \namended by inserting after subsection (g) the following:\n    ``(h)(1) A person who submits an application for registration to \nmanufacture or distribute a controlled substance in accordance with \nthis section may indicate on the registration application that the \nsubstance will be used only in connection with clinical trials of a \ndrug in accordance with section 505(i) of the Federal Food, Drug, and \nCosmetic Act.\n    ``(2) When an application for registration to manufacture or \ndistribute a controlled substance includes an indication that the \ncontrolled substance will be used only in connection with clinical \ntrials of a drug in accordance with section 505(i) of the Federal Food, \nDrug, and Cosmetic Act, the Attorney General shall--\n            ``(A) make a final decision on the application for \n        registration within 180 days; or\n            ``(B) provide notice to the applicant in writing of--\n                    ``(i) the outstanding issues that must be resolved \n                in order to reach a final decision on the application; \n                and\n                    ``(ii) the estimated date on which a final decision \n                on the application will be made.''.\n\nSEC. 4. REGISTRATION PROCESS UNDER CONTROLLED SUBSTANCES ACT.\n\n    (a) Definitions.--\n            (1) Factors as may be relevant to and consistent with the \n        public health and safety.--Section 303 of the Controlled \n        Substances Act (21 U.S.C. 823) is amended by adding at the end \n        the following:\n    ``(i) In this section, the phrase `factors as may be relevant to \nand consistent with the public health and safety' means factors that \nare relevant to and consistent with the findings contained in section \n101.''.\n            (2) Imminent danger to the public health or safety.--\n        Section 304(d) of the Controlled Substances Act (21 U.S.C. \n        824(d)) is amended--\n                    (A) by striking ``(d) The Attorney General'' and \n                inserting ``(d)(1) The Attorney General''; and\n                    (B) by adding at the end the following:\n    ``(2) In this subsection, the phrase `imminent danger to the public \nhealth or safety' means that, in the absence of an immediate suspension \norder, controlled substances will continue to be distributed or \ndispensed by a registrant who knows or should know through fulfilling \nthe obligations of the registrant under this Act, or has reason to \nbelieve that--\n            ``(A) the dispensing is outside the usual course of \n        professional practice;\n            ``(B) the distribution or dispensing poses a present or \n        foreseeable risk of adverse health consequences or death due to \n        the abuse or misuse of the controlled substances; or\n            ``(C) the controlled substances will continue to be \n        diverted outside of legitimate distribution channels.''.\n    (b) Opportunity To Submit Corrective Action Plan Prior to \nRevocation or Suspension.--Subsection (c) of section 304 of the \nControlled Substances Act (21 U.S.C. 824) is amended--\n            (1) by striking the last two sentences;\n            (2) by striking ``(c) Before'' and inserting ``(c)(1) \n        Before''; and\n            (3) by adding at the end the following:\n    ``(2) An order to show cause under paragraph (1) shall--\n            ``(A) contain a statement of the basis for the denial, \n        revocation, or suspension, including specific citations to any \n        laws or regulations alleged to be violated by the applicant or \n        registrant;\n            ``(B) direct the applicant or registrant to appear before \n        the Attorney General at a time and place stated in the order, \n        but not less than 30 days after the date of receipt of the \n        order; and\n            ``(C) notify the applicant or registrant of the opportunity \n        to submit a corrective action plan on or before the date of \n        appearance.\n    ``(3) Upon review of any corrective action plan submitted by an \napplicant or registrant pursuant to paragraph (2), the Attorney General \nshall determine whether denial, revocation or suspension proceedings \nshould be discontinued, or deferred for the purposes of modification, \namendment, or clarification to such plan.\n    ``(4) Proceedings to deny, revoke, or suspend shall be conducted \npursuant to this section in accordance with subchapter II of chapter 5 \nof title 5, United States Code. Such proceedings shall be independent \nof, and not in lieu of, criminal prosecutions or other proceedings \nunder this title or any other law of the United States.\n    ``(5) The requirements of this subsection shall not apply to the \nissuance of an immediate suspension order under subsection (d).''.\n\nSEC. 5. REPORT TO CONGRESS ON EFFECTS OF LAW ENFORCEMENT ACTIVITIES ON \n              PATIENT ACCESS TO MEDICATIONS.\n\n    (a) In General.--Not later than 1 year after the date of enactment \nof this Act, the Secretary of Health and Human Services, acting through \nthe Commissioner of Food and Drugs and the Director of the Centers for \nDisease Control and Prevention, and in consultation with the \nAdministrator of the Drug Enforcement Administration and the Director \nof National Drug Control Policy, shall submit a report to the \nCommittees on the Judiciary of the House of Representatives, the \nCommittee on Energy and Commerce of the House of Representatives, the \nCommittee on the Judiciary of the Senate, and the Committee on Health, \nEducation, Labor and Pensions of the Senate identifying--\n            (1) obstacles to legitimate patient access to controlled \n        substances;\n            (2) issues with diversion of controlled substances; and\n            (3) how collaboration between Federal, State, local, and \n        tribal law enforcement agencies and the pharmaceutical industry \n        can benefit patients and prevent diversion and abuse of \n        controlled substances.\n    (b) Consultation.--The report under subsection (a) shall \nincorporate feedback and recommendations from the following:\n            (1) Patient groups.\n            (2) Pharmacies.\n            (3) Drug manufacturers.\n            (4) Common or contract carriers and warehousemen.\n            (5) Hospitals, physicians, and other health care providers.\n            (6) State attorneys general.\n            (7) Federal, State, local, and tribal law enforcement \n        agencies.\n            (8) Health insurance providers and entities that provide \n        pharmacy benefit management services on behalf of a health \n        insurance provider.\n            (9) Wholesale drug distributors."
}